ClinicalTrials.gg
RecruitingNCT07403812Updated Oct 8, 2026

Assessing DCog Short for Neurotoxicity in CAR-T

An interventional study of DCog Short in Neurotoxicity, Neurotoxicity Syndromes and Hematologic Malignancy, sponsored by Beth Israel Deaconess Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Beth Israel Deaconess Medical Center · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.
Updated Oct 8, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 76 studies in Neurotoxicity Syndromes with a site in United States — 6 open to participants now, 11 under way, 3 of them phase 3. Neurotoxicity Syndromes · United States.

Planned enrollment
32nd of 52
40 · median 85
Started
2026
with 2 others
No phase
9 of 76
2 open now
Primary completion
2027-09
later than 9 of 10 live
Registered
74th of 76
by date

Among the 76 studies in Neurotoxicity Syndromes with a site in United States, this one is the 32nd largest by planned enrollment of the 52 interventional ones that give a count, is one of 3 that started in 2026, is one of 9 with no phase, reaches primary completion later than 9 of the 10 other live ones, and was the 74th registered.

Neurotoxicity Syndromes

133 studies on the registry are indexed under Neurotoxicity Syndromes; 17 are open to participants now.

Browse Neurotoxicity Syndromes studies →

Open to participants now

6 of the 76 studies in Neurotoxicity Syndromes with a site in United States are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 15 Neurotoxicity Syndromes studies recruiting now, 11 (73%) set no upper age limit and 1 (7%) stops at 75 or younger; none take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies in Neurotoxicity Syndromes with a site in United States, or all of them as a file.
02

Study summary

The aim of this study is to determine the effectiveness of DCog Short, a self-reporting, iPad-based application tool, in assessing neurotoxicity in participants undergoing CAR-T cell therapy.

Read the detailed description

The goal of this pilot study is to determine the effectiveness of DCog Short, a self-reporting, iPad-based application tool, in assessing neurotoxicity in participants undergoing CAR-T cell therapy. This is the first time investigators are examining this tool.

The U.S. Food and Drug Administration (FDA) has not approved DCOG Short as a mobile application tool to evaluate neurotoxicity for hematologic malignancies.

The research study procedures include screening for eligibility, questionnaires, and cognitive assessments.

It is expected that about 40 people will take part in this research study.

03

Conditions studied

  • Neurotoxicity
  • Neurotoxicity Syndromes
  • Hematologic Malignancy
  • Immune Effector Cell Associated Neurotoxicity Syndrome

Keywords

  • Neurotoxicity
  • Neurotoxicity Syndrome
  • Hematologic Malignancy
  • Immune Effector Cell Associated Neurotoxicity Syndrome
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • participants treated with CART-Cell therapy as described above and therefore at risk for treatment associated neurotoxicity.
  • Visual acuity of 20/100 or better.

Exclusion criteria

Exclusion Criteria:

  • patients \< 18 years old
  • pregnant women
  • prisoners
  • adults unable to consent,
  • participants unwilling to use iPad-based tools. Severe motor deficits that can prevent patients from using an iPad
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    CAR-T Cell Therapy Patients

    40 enrolled participants will complete: * Baseline visit * Daily study visits during hospitalization, then via phone: 2x weekly on days 14 - 21, then weekly on days 21 - 30 * 90 Day follow up visit

    Behavioral: DCog Short

Interventions

  • BehavioralDCog Short

    An iPad-based cognitive assessment instrument to evaluate neurotoxicity and consisting of a series of tests that measure various aspects of cognitive function. After hospital discharge, participants will be provided with iPads which will be returned at the 90 day follow up visit.

06

What researchers measure

Primary outcomes

  1. Sensitivity of DCog Short for Early Detection of Neurotoxicity

    Neurotoxicity is defined as any decrease from 10 on the Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) 10-point scale, where 10 indicates no impairment. The DCog Short assessment will be compared with the standard clinical ICANS evaluation to determine its ability to detect neurotoxicity on or before the onset of clinically confirmed ICANS. Sensitivity is defined as the proportion of patients with clinically confirmed ICANS for whom DCog Short indicates neurotoxicity on or before ICANS onset. DCog Short will be considered effective if sensitivity is ≥75% and non-promising if sensitivity is \<50%.

    Time frame: Until 30 days post CAR T-cell infusion, with frequency as described in the protocol schedule section 10.0.

  2. Specificity of DCog Short for Early Detection of Neurotoxicity

    Neurotoxicity is defined as any decrease from 10 on the Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) 10-point scale, where 10 indicates no impairment. The DCog Short assessment will be compared with the standard clinical ICANS evaluation to determine its ability to correctly identify patients who do not develop neurotoxicity. Specificity is defined as the proportion of patients who do not develop clinically confirmed ICANS and are not indicated by DCog Short. DCog Short will be considered effective if specificity is ≥75% and non-promising if specificity is \<50%.

    Time frame: Until 30 days post CAR T-cell infusion, with frequency as described in the protocol schedule section 10.0.

  3. Positive Predictive Value (PPV) of DCog Short for Early Detection of Neurotoxicity

    Neurotoxicity is defined as any decrease from 10 on the Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) 10-point scale, where 10 indicates no impairment. The DCog Short assessment will be compared with the standard clinical ICANS evaluation to determine its ability to correctly identify patients who do not develop neurotoxicity. Positive predictive value is defined as the proportion of patients indicated by DCog Short who subsequently develop Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) based on standard clinical assessment.

    Time frame: Until 30 days post CAR T-cell infusion, with frequency as described in the protocol schedule section 10.0.

  4. Negative Predictive Value (NPV) of DCog Short for Early Detection of Neurotoxicity

    Neurotoxicity is defined as any decrease from 10 on the Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) 10-point scale, where 10 indicates no impairment. The DCog Short assessment will be compared with the standard clinical ICANS evaluation to determine its ability to correctly identify patients who do not develop neurotoxicity. Negative predictive value is defined as the proportion of patients not indicated by DCog Short who do not develop Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) based on standard clinical assessment.

    Time frame: Until 30 days post CAR T-cell infusion, with frequency as described in the protocol schedule section 10.0.

  5. Raw Accuracy of DCog Short for Early Detection of Neurotoxicity

    Neurotoxicity is defined as any decrease from 10 on the Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) 10-point scale, where 10 indicates no impairment. The DCog Short assessment will be compared with the standard clinical ICANS evaluation to determine its ability to correctly identify patients who do not develop neurotoxicity. Raw accuracy is defined as the proportion of patients correctly classified by DCog Short, including both patients who develop Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) and those who do not, based on standard clinical assessment.

    Time frame: Until 30 days post CAR T-cell infusion, with frequency as described in the protocol schedule section 10.0.

Secondary outcomes

  1. Immune Effector Cell-Associated Encephalopathy (CARTOX-10) Score Change from Baseline

    For ICANS detection and monitoring, the Immune Effector Cell-Associated Encephalopathy (ICE) score, also called CARTOX-10, will be used. The total score ranges from 0 to 10, with higher scores indicating normal cognitive function. Detailed scoring instructions and grading criteria are provided in Appendix A of the protocol.

    Time frame: Until 30 days post CAR T-cell infusion, with frequency as described in the protocol schedule section 10.0.

  2. Differences in Neurotoxicity Development and Detection Across CAR T-Cell Therapy Types

    Neurotoxicity will be monitored using DCog Short and CARTOX-10 assessments throughout the study period. Immune Effector Cell-Associated Encephalopathy (ICE) score, e ranges from 0 to 10, with higher scores indicating normal cognitive function. Detailed scoring instructions and grading criteria are provided in Appendix A of the protocol.

    Time frame: Until 30 days post CAR T-cell infusion, with frequency as described in the protocol schedule section 10.0.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data can be shared no earlier than 1 year following the date of publication

Access criteria: Contact the Beth Israel Deaconess Medical Center Technology Ventures Office at tvo@bidmc.harvard.edu

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Apr 2026 (actual). Primary completion is estimated for Sep 2027, 17 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 8, 2026: start Jul 2026 → Apr 2026, primary completion Aug 2026 → Sep 2027 and completion Aug 2027 → Aug 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2026
First posted
Feb 11, 2026
StartActual
Apr 13, 2026was Jul 2026
Primary completionEst.
Sep 30, 2027was Aug 2026
CompletionEst.
Aug 31, 2028was Aug 2027
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 8, 2026
Sites
Beth Israel Deaconess Medical Center is now Recruiting
Oct 8, 2026
Start date
Jul 2026→Apr 13, 2026 (actual)
Oct 8, 2026
Primary completion
Aug 31, 2026→Sep 30, 2027
Oct 8, 2026
Study completion
Aug 31, 2027→Aug 31, 2028
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    Not yet recruiting→Recruiting
    Beth Israel Deaconess Medical Center is now Recruiting
    Start date Jul 2026→Apr 13, 2026 (now actual)
    Primary completion Aug 31, 2026→Sep 30, 2027
    Study completion Aug 31, 2027→Aug 31, 2028
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07403812
Responsible party
Jon Arnason (Principal Investigator, Beth Israel Deaconess Medical Center) — Principal investigator
First posted
Feb 11, 2026
Start date
Apr 13, 2026
Primary completion
Sep 30, 2027 (estimated)
Completion
Aug 31, 2028 (estimated)
Last update
Oct 8, 2026

Study contacts

Jon Arnason, MD
Contact
jarnason@bidmc.harvard.edu
(617) 667-9920
Jon Arnason, MD
principal investigator · Beth Israel Deaconess Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion